🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Next-Gen Oral Therapeutics for Type 2 Diabetes
Organization BIOTHERAPEUTICS, INC.Location Blacksburg, UNITED STATESPosted 1 Jul 2025Deadline 31 Dec 2025 ⚠️
NIHUS FederalResearch GrantFY202521+ years oldAbscisic AcidAbscissic AcidAbscissinsAccelerationAdipocytesAdipose CellAdipose tissueAdultAdult HumanAdult-Onset Diabetes MellitusAgonistArea Under CurveAutoimmune DiseasesB-Cell Differentiation Factor GeneB-Cell Stimulatory Factor 2 GeneBSF-2 GeneBSF2 GeneBenignBeta-2 Gene InterferonBindingBioavailabilityBiological AvailabilityBiological Response Modifier TherapyBiological TherapyBiotechBiotechnologyBloodBlood GlucoseBlood PlasmaBlood Reticuloendothelial SystemBlood SugarBody WeightBody Weight ChangesCCL2CCL2 geneCause of DeathCell BodyCell RespirationCellsCellular Metabolic ProcessCellular RespirationChemokine, CC Motif, Ligand 2ChronicChronic DiseaseChronic IllnessClinicalClinical EvaluationClinical TestingCo-cultureCocultivationCocultureCoculture TechniquesCombined Modality TherapyComputer ModelsComputerized ModelsD-GlucoseDevelopmentDextroseDiabetes MellitusDiabetic mouseDimethylbiguanidineDimethylguanylguanidineDiseaseDisorderDoseDose LimitingDrugsEmbryonic Muscle CellsFastingFat CellsFatty TissueGLP-1 receptorGLP-I receptorGLUT 4 proteinGLUT4GLUT4 geneGLUT4 proteinGeneticGlucoseGlucose tolerance testGlycated HemoglobinsGlycosylated HemoglobinGoalsGuidelinesHSF GeneHepatocyte Stimulatory Factor GeneHumanHumulin RHybridoma Growth Factor GeneHypertensionHypertrophyIFNB2 GeneIL-6 GeneIL6IL6 geneIND FilingIND applicationIND packageIND submissionIPGTTImmunomodulationImpairmentInfiltrationInflammationInflammatoryInflammatory InfiltrateInsulinInsulin ResistanceInterleukin 6 (Interferon, Beta 2) GeneInterleukin-6 GeneInvestigational New Drug ApplicationKetosis-Resistant Diabetes MellitusLeadLife StyleLifestyleLigandsLigaseLigase GeneLipocytesLipolysisMCAFMCP-1MCP1MacrophageMammaliaMammalsMarketingMature LipocyteMature fat cellMaturity-Onset Diabetes MellitusMediatingMedicationMetabolicMetforminMiceMice MammalsModern ManMolecular InteractionMonocyte Chemoattractant Protein-1Monocyte Chemotactic Protein-1Monocyte Chemotactic and Activating FactorMonocyte Chemotactic and Activating ProteinMonocyte Chemotactive and Activating FactorMonocyte Secretory Protein JEMultimodal TherapyMultimodal TreatmentMurineMusMuscle FibersMuscle functionMyoblastsMyotubesMφN,N-dimethyl-imidodicarbonimidic diamideNIDDMNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusNovolin RObesityOralOutcomePathway interactionsPatientsPb elementPersonsPharmaceutical PreparationsPhasePhosphorylationPhysiologic AvailabilityPhytohormonesPlant Growth RegulatorsPlant HormonesPlasmaPlasma SerumPrecursor Muscle CellsPrediabetesPrediabetes syndromePrediabetic StateProtein PhosphorylationPublic HealthQOLQuality of lifeReceptor ProteinRegular InsulinRegulatory T-LymphocyteReticuloendothelial System, Serum, PlasmaRhabdomyocyteSBIRSCYA2SafetySkeletal FiberSkeletal MuscleSkeletal Muscle CellSkeletal Muscle FiberSkeletal MyoblastsSkeletal MyocytesSlow-Onset Diabetes MellitusSmall Business Innovation ResearchSmall Business Innovation Research GrantSmall Inducible Cytokine A2Stable Diabetes MellitusSynthetasesT2 DMT2DT2DMTherapeuticToxic effectToxicitiesTreatment EfficacyTregType 2 Diabetes MellitusType 2 diabetesType II Diabetes MellitusType II diabetesVascular Hypertensive DiseaseVascular Hypertensive DisorderVisceralVoluntary MuscleWeightWeight Changeadherence rateadipocyte developmentadipocyte differentiationadiposeadiposityadult onset diabetesadulthoodaerobic metabolismaerobic respirationautoimmune conditionautoimmune disorderautoimmunity diseasebiological therapeuticbiological treatmentbiologically based therapeuticsbiotherapeuticsbiotherapyblood lipidcell metabolismcellular metabaolismchronic disorderclinical testcombination therapycombined modality treatmentcombined treatmentcommercial applicationcomparativecomputational modelingcomputational modelscomputer based modelscomputerized modelingcorpulencecytokinedb/db mousedesigndesigningdevelopmentaldiabetesdiabetes mouse modeldiabetes pathogenesisdiabeticdiabetic patientdiet-associated obesitydiet-induced obesitydiet-related obesitydietarydisabilitydrug candidatedrug/agentfastedfastsfat metabolismfatty acid oxidationflexibilityflexiblefruits and vegetablesglucagon-like peptide-1 receptorglucose toleranceglucose uptakeglycemic controlhead-to-head analysishead-to-head comparisonheavy metal Pbheavy metal leadhigh blood pressurehigh riskhyperpiesiahyperpiesishypertensive diseasehypertensive disorderimmune modulationimmune regulationimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimprovedindexinginsulin resistantinsulin sensitivityinsulin sensitivity testinsulin toleranceinsulin tolerance testinsulin-induced hypoglycemia testinsulin-responsive glucose transporterintervention efficacyintraperitoneal glucose tolerance testketosis resistant diabeteslanthioninelipid metabolismmaturity onset diabetesmouse modelmulti-modal therapymulti-modal treatmentmurine modelnew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnext generationnovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetoxidationoxidative metabolismpandemicpandemic diseasepathwaypatient populationpre-diabetespre-diabeticprecision medicineprecision-based medicineprediabeticpublic health relevancereceptorregulatory T-cellsresearch clinical testingsmall molecule therapeuticstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic candidatetherapeutic efficacytherapeutic targettherapy efficacytranslational opportunitiestranslational potentialtype 2 DMtype II DMtype two diabetesweightswhite adipose tissueyellow adipose tissue
Applications closed.
Description preview
Next-Gen Oral Therapeutics for Type 2 Diabetes
BioTherapeutics Inc (BTI) is a clinical-stage biotech company that synergistically combines the power of
advanced computational modeling with translational and clinical experimentation to accelerate the development
of novel precision medicine therapeutics for inflammatory and autoimmune diseases. The…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click